PAHC — Phibro Animal Health Corporation

Phibro Animal Health Corporation (PAHC) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Consolidated Net Sales: $373.9 million, up 21% year-over-year.
• Animal Health Segment Sales: Grew 26% to $290 million.
• Adjusted EBITDA: Increased 41% to $82.2 million.
• Adjusted Net Income: Up 60%, with adjusted diluted EPS increasing 58%.
• Free Cash Flow: Generated $47 million over the past twelve months.
• Gross Leverage Ratio: 3.1 times; Net Leverage Ratio: 2.8 times.
• Quarterly Dividend: Maintained at 12¢ per share.

2. Strategic Updates and Business Highlights:

• Growth Drivers: Strong performance in medicated feed additives (34% growth) and vaccines, particularly in Latin America.
• Integration Success: The integration of the MFA portfolio is yielding positive results, contributing significantly to sales growth.
• Cultural and Operational Momentum: Leadership meetings and industry events highlighted strong alignment and enthusiasm among teams, indicating a robust corporate culture.
• Phibro Forward Strategy: Focus on sustainability and profitability through R&D investments and digital capabilities, aiming to drive future growth.

3. Forward Guidance and Outlook:

• Revised Guidance for FY 2026:
  • Net Sales: Increased to a range of $1.450 billion to $1.500 billion (12% to 16% growth).
  • Adjusted EBITDA: Raised to $245 million to $255 million (33% to 39% growth).
  • Adjusted Net Income: Increased to $120 million to $127 million (41% to 49% growth).
• Continued Market Confidence: Positive sentiment in the protein markets, with expectations for sustained demand and growth.

4. Bad News, Challenges, or Points of Concern:

• Legacy MFA Business: Experienced a 5% decline due to timing issues with a large customer, although expected to normalize in Q3.
• Performance Products Segment: Declined by 10%, indicating potential weakness in this area.
• Inventory Management: Increased inventory levels due to tariffs and demand pressures could impact cash flow stability in the short term.

5. Notable Q&A Insights:

• Gross Margin Drivers: Strong pricing power, favorable product mix, and internal focus on high-margin products contributed to improved margins.
• MFA Business Outlook: Anticipated recovery in legacy MFA sales in the second half of the year, with expectations of low to mid-single-digit growth long-term.
• Sustainability of Market Demand: Continued strong demand for clean proteins across various livestock sectors, although potential trade shifts and disease outbreaks could pose risks.
• Innovation in Companion Animal Segment: New products, especially in oral health, are expected to contribute more significantly in FY 2027 rather than the current year.

This summary encapsulates the key takeaways from Phibro Animal Health Corporation's Q2 2026 earnings call, highlighting both the positive momentum and the challenges faced by the company.